KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Change in Receivables (2016 - 2025)

Globus Medical's Change in Receivables history spans 15 years, with the latest figure at $64.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 385.34% year-over-year to $64.2 million; the TTM value through Dec 2025 reached $52.2 million, down 33.15%, while the annual FY2025 figure was $52.2 million, 33.15% down from the prior year.
  • Change in Receivables reached $64.2 million in Q4 2025 per GMED's latest filing, up from $8.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $87.8 million in Q2 2024 to a low of -$23.7 million in Q3 2024.
  • Average Change in Receivables over 5 years is $12.8 million, with a median of $8.6 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: skyrocketed 510.97% in 2023, then tumbled 371.47% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $6.0 million in 2021, then fell by 22.19% to $4.6 million in 2022, then soared by 179.15% to $13.0 million in 2023, then tumbled by 273.47% to -$22.5 million in 2024, then skyrocketed by 385.34% to $64.2 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Change in Receivables are $64.2 million (Q4 2025), $8.4 million (Q3 2025), and $2.2 million (Q2 2025).